Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California.

[1]  S. Daneshmand,et al.  Lymph node dissection technique is more important than lymph node count in identifying nodal metastases in radical cystectomy patients: a comparative mapping study. , 2011, European urology.

[2]  V. Kataja,et al.  Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  L. Lacombe,et al.  Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience , 2011, BJU international.

[4]  E. Kikuchi,et al.  Neoadjuvant gemcitabine plus cisplatin for muscle-invasive bladder cancer. , 2011, Japanese journal of clinical oncology.

[5]  M. Eliasziw,et al.  Referral and treatment rates of neoadjuvant chemotherapy in muscle-invasive bladder cancer before and after publication of a clinical practice guideline. , 2010, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[6]  E. Klein,et al.  Lack of pathologic down‐staging with neoadjuvant chemotherapy for muscle‐invasive urothelial carcinoma of the bladder , 2009, Cancer.

[7]  P. Russo,et al.  A role for neoadjuvant gemcitabine plus cisplatin in muscle‐invasive urothelial carcinoma of the bladder , 2008, Cancer.

[8]  R. Dienstmann,et al.  Phase II trial of neoadjuvant gemcitabine and cisplatin in patients with resectable bladder carcinoma , 2007 .

[9]  P. Carroll,et al.  Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. , 2007, The Journal of urology.

[10]  S. Groshen,et al.  Radical cystectomy with extended lymphadenectomy: evaluating separate package versus en bloc submission for node positive bladder cancer. , 2007, The Journal of urology.

[11]  Michael W Kattan,et al.  Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  T. Seufferlein,et al.  Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  S. Ricci,et al.  Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer , 2005 .

[14]  J. Chin,et al.  Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. , 2004, The Journal of urology.

[15]  Nicholas J Vogelzang,et al.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. , 2003, The New England journal of medicine.

[16]  C. Vale.  Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis , 2003, The Lancet.

[17]  H. Schmoll,et al.  F.L. Greene, D.L. Page, I.D. Fleming et al. (eds). AJCC Cancer Staging Manual, 6th edition , 2003 .

[18]  S. Groshen,et al.  Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  W T McGivney,et al.  The National Comprehensive Cancer Network , 1998, Cancer.

[20]  Derick R. Peterson,et al.  Neoadjuvant gemcitabine and cisplatin chemotherapy for locally advanced urothelial cancer of the bladder , 2012, Cancer.

[21]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[22]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[23]  M. Brennan,et al.  Follow-up [2] , 1992 .